The role of macrophage IL-10/innate IFN interplay during virus-induced asthma

Reviews in Medical Virology

Volumn 25, Issue 1, 2015, Pages 33-49

  Zdrenghea, Mihnea T ^a,b   Makrinioti, Heidi ^c,d,e   Muresan, Adriana ^b   Johnston, Sebastian L ^c,d,e   Stanciu, Luminita A ^b,c,d,e  

^a THE ONCOLOGY INSTITUTE PROF DR ION CHIRICUTA   (Romania)

^b IULIU HATIEGANU UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^c NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^d KING'S COLLEGE LONDON   (United Kingdom)

^e Centre for Respiratory Infections   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INTERFERON; INTERLEUKIN 10;

ARTICLE; ASTHMA; CYTOKINE PRODUCTION; DISEASE EXACERBATION; IMMUNE RESPONSE; IMMUNOREGULATION; MACROPHAGE; NONHUMAN; VIRUS INFECTION; ANIMAL; GENETICS; HUMAN; IMMUNOLOGY; VIROLOGY; VIRUS;

ANIMALS; ASTHMA; HUMANS; INTERFERONS; INTERLEUKIN-10; MACROPHAGES; VIRUS DISEASES; VIRUSES;

EID: 84920964291     PISSN: 10529276     EISSN: 10991654     Source Type: Journal    
DOI: 10.1002/rmv.1817     Document Type: Article

References (150)

1. Johnston NW, Sears MR. Asthma exacerbations. 1: epidemiology. Thorax 2006; 61: 722-728. DOI: 10.1136/thx.2005.045161
2. Greenberg S. Asthma exacerbations: predisposing factors and prediction rules. Current Opinion in Allergy and Clinical Immunology 2013; 13: 225-236. DOI: 10.1097/ACI.0b013e32836096de
3. Johnston SL, Pattemore PK, Sanderson G, et al. Community study of role of viral infections in exacerbations of asthma in 9-11 year old children. BMJ 1995; 310: 1225-1229.
4. Busse WW, Lemanske RF Jr., Gern JE. Role of viral respiratory infections in asthma and asthma exacerbations. Lancet 2010; 376: 826-834. DOI: 10.1016/S0140-6736(10)61380-3
5. Ogawa Y, Duru EA, Ameredes BT. Role of IL-10 in the resolution of airway inflammation. Current Molecular Medicine 2008; 8: 437-445.
6. Martinez FO. The transcriptome of human monocyte subsets begins to emerge. Journal of Biology 2009; 8: 99. DOI: 10.1186/jbiol206
7. Martinez FO, Helming L, Gordon S. Alternative activation of macrophages: an immunologic functional perspective. Annual Review of Immunology 2009; 27: 451-483. DOI: 10.1146/annurev.immunol.021908.132532
8. Gordon S, Martinez FO. Alternative activation of macrophages: mechanism and functions. Immunity 2010; 32: 593-604. DOI: 10.1016/j.immuni.2010.05.007
9. Krausgruber T, Blazek K, Smallie T, et al. IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nature Immunology 2011; 12: 231-238. DOI: 10.1038/ni.1990
10. Pechkovsky DV, Prasse A, Kollert F, et al. Alternatively activated alveolar macrophages in pulmonary fibrosis-mediator production and intracellular signal transduction. Clinical Immunology 2010; 137: 89-101. DOI: 10.1016/j.clim.2010.06.017
11. Wang HW, Joyce JA. Alternative activation of tumor-associated macrophages by IL-4: priming for protumoral functions. Cell Cycle 2010; 9: 4824-4835.
12. Wynn TA. Fibrotic disease and the T(H)1/T(H)2 paradigm. Nature Reviews Immunology 2004; 4: 583-594. DOI: 10.1038/nri1412
13. Sindrilaru A, Peters T, Wieschalka S, et al. An unrestrained proinflammatory M1 macrophage population induced by iron impairs wound healing in humans and mice. Journal of Clinical Investigation 2011; 121: 985-997. DOI: 10.1172/JCI44490
14. Leidi M, Gotti E, Bologna L, et al. M2 macrophages phagocytose rituximab-opsonized leukemic targets more efficiently than m1 cells in vitro. Journal of Immunology 2009; 182: 4415-4422. DOI: 10.4049/jimmunol.0713732
15. Wynn TA. Cellular and molecular mechanisms of fibrosis. Journal of Pathology 2008; 214: 199-210. DOI: 10.1002/path.2277
16. Martinez FO, Sica A, Mantovani A, Locati M. Macrophage activation and polarization. Frontiers in Bioscience 2008; 13: 453-461.
17. Stout RD, Jiang C, Matta B, Tietzel I, Watkins SK, Suttles J. Macrophages sequentially change their functional phenotype in response to changes in microenvironmental influences. Journal of Immunology 2005; 175: 342-349.
18. Mylonas KJ, Nair MG, Prieto-Lafuente L, Paape D, Allen JE. Alternatively activated macrophages elicited by helminth infection can be reprogrammed to enable microbial killing. Journal of Immunology 2009; 182: 3084-3094. DOI: 10.4049/jimmunol.0803463
19. Cassol E, Cassetta L, Rizzi C, Alfano M, Poli G. M1 and M2a polarization of human monocyte-derived macrophages inhibits HIV-1 replication by distinct mechanisms. Journal of Immunology 2009; 182: 6237-6246. DOI: 182/10/6237 [pii] 10.4049/jimmunol.0803447
20. Xu W, Zhao X, Daha MR, van Kooten C. Reversible differentiation of pro- and anti-inflammatory macrophages. Molecular Immunology 2013; 53: 179-186. DOI: 10.1016/j.molimm.2012.07.005
21. Biswas SK, Mantovani A. Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm. Nature Immunology 2010; 11: 889-896. DOI: 10.1038/ni.1937
22. Egawa M, Mukai K, Yoshikawa S, et al. Inflammatory monocytes recruited to allergic skin acquire an anti-inflammatory M2 phenotype via basophil-derived interleukin-4. Immunity 2013; 38: 570-580. DOI: 10.1016/j.immuni.2012.11.014
23. Martinez FO, Helming L, Milde R, et al. Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: similarities and differences. Blood 2013; 121: e57-e69. DOI: 10.1182/blood-2012-06-436212
24. Jenkins SJ, Ruckerl D, Cook PC, et al. Local macrophage proliferation, rather than recruitment from the blood, is a signature of TH2 inflammation. Science 2011; 332: 1284-1288. DOI: 10.1126/science.1204351
25. Davies LC, Rosas M, Smith PJ, Fraser DJ, Jones SA, Taylor PR. A quantifiable proliferative burst of tissue macrophages restores homeostatic macrophage populations after acute inflammation. European Journal of Immunology 2011; 41: 2155-2164. DOI: 10.1002/eji.201141817
26. Hashimoto D, Chow A, Noizat C, et al. Tissue-resident macrophages self-maintain locally throughout adult life with minimal contribution from circulating monocytes. Immunity 2013; 38: 792-804.
27. Yoon SI, Logsdon NJ, Sheikh F, Donnelly RP, Walter MR. Conformational changes mediate interleukin-10 receptor 2 (IL-10R2) binding to IL-10 and assembly of the signaling complex. Journal of Biological Chemistry 2006; 281: 35088-35096.
28. Wolk K, Kunz S, Asadullah K, Sabat R. Cutting edge: immune cells as sources and targets of the IL-10 family members? Journal of Immunology 2002; 168: 5397-5402.
29. Moore KW, de Waal Malefyt R, Coffman RL, O'Garra A. Interleukin-10 and the interleukin-10 receptor. Annual Review of Immunology 2001; 19: 683-765.
30. Wolk K, Witte E, Reineke U, et al. Is there an interaction between interleukin-10 and interleukin-22? Genes and Immunity 2005; 6: 8-18.
31. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. IL-22 increases the innate immunity of tissues. Immunity 2004; 21: 241-254. DOI: 10.1016/j.immuni.2004.07.007S1074761304001943 [pii]
32. Wolk K, Haugen HS, Xu W, et al. IL-22 and IL-20 are key mediators of the epidermal alterations in psoriasis while IL-17 and IFN-gamma are not. Journal of Molecular Medicine (Berlin) 2009; 87: 523-536. DOI: 10.1007/s00109-009-0457-0
33. Logsdon NJ, Jones BC, Josephson K, Cook J, Walter MR. Comparison of interleukin-22 and interleukin-10 soluble receptor complexes. Journal of Interferon & Cytokine Research 2002; 22: 1099-1112. DOI: 10.1089/10799900260442520
34. Commins S, Steinke JW, Borish L. The extended IL-10 superfamily: IL-10, IL-19, IL-20, IL-22, IL-24, IL-26, IL-28, and IL-29. Journal of Allergy and Clinical Immunology 2008; 121: 1108-1111. DOI: 10.1016/j.jaci.2008.02.026
35. Tebo JM, Kim HS, Gao J, Armstrong DA, Hamilton TA. Interleukin-10 suppresses IP-10 gene transcription by inhibiting the production of class I interferon. Blood 1998; 92: 4742-4749.
36. Gary-Gouy H, Lebon P, Dalloul AH. Type I interferon production by plasmacytoid dendritic cells and monocytes is triggered by viruses, but the level of production is controlled by distinct cytokines. Journal of Interferon & Cytokine Research 2002; 22: 653-659.
37. Staples KJ, Smallie T, Williams LM, et al. IL-10 induces IL-10 in primary human monocyte-derived macrophages via the transcription factor Stat3. Journal of Immunology 2007; 178: 4779-4785. DOI: 178/8/4779 [pii]
38. Murray PJ. The JAK-STAT signaling pathway: input and output integration. Journal of Immunology 2007; 178: 2623-2629.
39. Niemand C, Nimmesgern A, Haan S, et al. Activation of STAT3 by IL-6 and IL-10 in primary human macrophages is differentially modulated by suppressor of cytokine signaling 3. Journal of Immunology 2003; 170: 3263-3272.
40. Tiemessen MM, Jagger AL, Evans HG, van Herwijnen MJ, John S, Taams LS. CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proceedings of the National Academy of Sciences of the United States of America 2007; 104: 19446-19451. DOI: 10.1073/pnas.0706832104
41. Brooks DG, Walsh KB, Elsaesser H, Oldstone MB. IL-10 directly suppresses CD4 but not CD8 T cell effector and memory responses following acute viral infection. Proceedings of the National Academy of Sciences of the United States of America 2010; 107: 3018-3023. DOI: 10.1073/pnas.0914500107
42. Biswas PS, Pedicord V, Ploss A, Menet E, Leiner I, Pamer EG. Pathogen-specific CD8 T cell responses are directly inhibited by IL-10. Journal of Immunology 2007; 179: 4520-4528.
43. Chuntharapai A, Gibbs V, Lu J, et al. Determination of residues involved in ligand binding and signal transmission in the human IFN-alpha receptor 2. Journal of Immunology 1999; 163: 766-773.
44. Francois-Newton V, Livingstone M, Payelle-Brogard B, Uze G, Pellegrini S. USP18 establishes the transcriptional and anti-proliferative interferon alpha/beta differential. Biochemical Journal 2012; 446: 509-516. DOI: 10.1042/BJ20120541
45. Gough DJ, Messina NL, Hii L, et al. Functional crosstalk between type I and II interferon through the regulated expression of STAT1. PLoS Biology 2010; 8: e1000361. DOI: 10.1371/journal.pbio.1000361
46. Gough DJ, Messina NL, Clarke CJ, Johnstone RW, Levy DE. Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity 2012; 36: 166-174. DOI: 10.1016/j.immuni.2012.01.011
47. Mogensen SC, Virelizier JL. The interferon-macrophage alliance. Interferon 1987; 8: 55-84.
48. Basagoudanavar SH, Thapa RJ, Nogusa S, Wang J, Beg AA, Balachandran S. Distinct roles for the NF-kappa B RelA subunit during antiviral innate immune responses. Journal of Virology 2011; 85: 2599-2610. DOI: 10.1128/JVI.02213-10
49. Balachandran S, Beg AA. Defining emerging roles for NF-kappaB in antivirus responses: revisiting the interferon-beta enhanceosome paradigm. PLoS Pathogen 2011; 7: e1002165. DOI: 10.1371/journal.ppat.1002165
50. Wang WB, Levy DE, Lee CK. STAT3 negatively regulates type I IFN-mediated antiviral response. Journal of Immunology 2011; 187: 2578-2585. DOI: 10.4049/jimmunol.1004128
51. Wathelet MG, Lin CH, Parekh BS, Ronco LV, Howley PM, Maniatis T. Virus infection induces the assembly of coordinately activated transcription factors on the IFN-beta enhancer in vivo. Molecular Cell 1998; 1: 507-518.
52. Kumar KP, McBride KM, Weaver BK, Dingwall C, Reich NC. Regulated nuclear-cytoplasmic localization of interferon regulatory factor 3, a subunit of double-stranded RNA-activated factor 1. Molecular and Cellular Biology 2000; 20: 4159-4168.
53. Kotenko SV, Gallagher G, Baurin VV, et al. IFN-lambdas mediate antiviral protection through a distinct class II cytokine receptor complex. Nature Immunology 2003; 4: 69-77.
54. Thomson SJ, Goh FG, Banks H, et al. The role of transposable elements in the regulation of IFN-lambda1 gene expression. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 11564-11569. DOI: 10.1073/pnas.0904477106
55. Osterlund PI, Pietila TE, Veckman V, Kotenko SV, Julkunen I. IFN regulatory factor family members differentially regulate the expression of type III IFN (IFN-lambda) genes. Journal of Immunology 2007; 179: 3434-3442.
56. Onoguchi K, Yoneyama M, Takemura A, et al. Viral infections activate types I and III interferon genes through a common mechanism. Journal of Biological Chemistry 2007; 282: 7576-7581.
57. Osterlund P, Veckman V, Siren J, et al. Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells. Journal of Virology 2005; 79: 9608-9617.
58. Siren J, Pirhonen J, Julkunen I, Matikainen S. IFN-alpha regulates TLR-dependent gene expression of IFN-alpha, IFN-beta, IL-28, and IL-29. Journal of Immunology 2005; 174: 1932-1937.
59. Dai J, Megjugorac NJ, Amrute SB, Fitzgerald-Bocarsly P. Regulation of IFN regulatory factor-7 and IFN-alpha production by enveloped virus and lipopolysaccharide in human plasmacytoid dendritic cells. Journal of Immunology 2004; 173: 1535-1548.
60. Mordstein M, Neugebauer E, Ditt V, et al. Lambda interferon renders epithelial cells of the respiratory and gastrointestinal tracts resistant to viral infections. Journal of Virology 2010; 84: 5670-5677. DOI: 10.1128/JVI.00272-10
61. Ioannidis I, Ye F, McNally B, Willette M, Flano E. Toll-like receptor expression and induction of type I and type III interferons in primary airway epithelial cells. Journal of Virology 2013; 87: 3261-3270. DOI: 10.1128/JVI.01956-12
62. Iversen MB, Paludan SR. Mechanisms of type III interferon expression. Journal of Interferon & Cytokine Research 2010; 30: 573-578. DOI: 10.1089/jir.2010.0063
63. Levy DE, Marie IJ, Durbin JE. Induction and function of type I and III interferon in response to viral infection. Current Opinion in Virology 2011; 1: 476-486. DOI: 10.1016/j.coviro.2011.11.001
64. Durbin RK, Kotenko SV, Durbin JE. Interferon induction and function at the mucosal surface. Immunology Reviews 2013; 255: 25-39. DOI: 10.1111/imr.12101
65. Porta C, Rimoldi M, Raes G, et al. Tolerance and M2 (alternative) macrophage polarization are related processes orchestrated by p50 nuclear factor kappaB. Proceedings of the National Academy of Sciences of the United States of America 2009; 106: 14978-14983. DOI: 0809784106 [pii] 10.1073/pnas.0809784106
66. Crittenden MR, Cottam B, Savage T, Nguyen C, Newell P, Gough MJ. Expression of NF-kappaB p50 in tumor stroma limits the control of tumors by radiation therapy. PLoS ONE 2012; 7: e39295. DOI: 10.1371/journal.pone.0039295
67. Siegel R, Eskdale J, Gallagher G. Regulation of IFN-lambda1 promoter activity (IFN-lambda1/IL-29) in human airway epithelial cells. Journal of Immunology 2011; 187: 5636-5644. DOI: 10.4049/jimmunol.1003988
68. Zhou Z, Hamming OJ, Ank N, Paludan SR, Nielsen AL, Hartmann R. Type III interferon (IFN) induces a type I IFN-like response in a restricted subset of cells through signaling pathways involving both the Jak-STAT pathway and the mitogen-activated protein kinases. Journal of Virology 2007; 81: 7749-7758. DOI: 10.1128/JVI.02438-06
69. Sommereyns C, Paul S, Staeheli P, Michiels T. IFN-lambda (IFN-lambda) is expressed in a tissue-dependent fashion and primarily acts on epithelial cells in vivo. PLoS Pathogen 2008; 4: e1000017. DOI: 10.1371/journal.ppat.1000017
70. Witte K, Gruetz G, Volk HD, et al. Despite IFN-lambda receptor expression, blood immune cells, but not keratinocytes or melanocytes, have an impaired response to type III interferons: implications for therapeutic applications of these cytokines. Genes and Immunity 2009; 10: 702-714. DOI: 10.1038/gene.2009.72
71. Wolk K, Witte K, Witte E, et al. Maturing dendritic cells are an important source of IL-29 and IL-20 that may cooperatively increase the innate immunity of keratinocytes. Journal of Leukocyte Biology 2008; 83: 1181-1193. DOI: jlb.0807525 [pii] 10.1189/jlb.0807525
72. Hou W, Wang X, Ye L, et al. Lambda interferon inhibits human immunodeficiency virus type 1 infection of macrophages. Journal of Virology 2009; 83: 3834-3842. DOI: JVI.01773-08 [pii] 10.1128/JVI.01773-08
73. Liu BS, Janssen HL, Boonstra A. IL-29 and IFNalpha differ in their ability to modulate IL-12 production by TLR-activated human macrophages and exhibit differential regulation of the IFNgamma receptor expression. Blood 2011; 117: 2385-2395. DOI: 10.1182/blood-2010-07-298976
74. Doyle SE, Schreckhise H, Khuu-Duong K, et al. Interleukin-29 uses a type 1 interferon-like program to promote antiviral responses in human hepatocytes. Hepatology 2006; 44: 896-906.
75. Gad HH, Dellgren C, Hamming OJ, Vends S, Paludan SR, Hartmann R. Interferon-lambda is functionally an interferon but structurally related to the interleukin-10 family. Journal of Biological Chemistry 2009; 284: 20869-20875. DOI: M109.002923 [pii] 10.1074/jbc.M109.002923
76. Donnelly RP, Dickensheets H, O'Brien TR. Interferon-lambda and therapy for chronic hepatitis C virus infection. Trends in Immunology 2011; 32: 443-450. DOI: 10.1016/j.it.2011.07.002
77. Dumoutier L, Tounsi A, Michiels T, Sommereyns C, Kotenko SV, Renauld JC. Role of the interleukin (IL)-28 receptor tyrosine residues for antiviral and antiproliferative activity of IL-29/interferon-lambda 1: similarities with type I interferon signaling. Journal of Biological Chemistry 2004; 279: 32269-32274. DOI: 10.1074/jbc.M404789200
78. Meager A, Visvalingam K, Dilger P, Bryan D, Wadhwa M. Biological activity of interleukins-28 and -29: comparison with type I interferons. Cytokine 2005; 31: 109-118.
79. Jordan WJ, Eskdale J, Srinivas S, et al. Human interferon lambda-1 (IFN-lambda1/IL-29) modulates the Th1/Th2 response. Genes and Immunity 2007; 8: 254-261.
80. Pekarek V, Srinivas S, Eskdale J, Gallagher G. Interferon lambda-1 (IFN-lambda1/IL-29) induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. Genes and Immunity 2007; 8: 177-180. DOI: 6364372 [pii] 10.1038/sj.gene.6364372
81. Huber JP, Ramos HJ, Gill MA, Farrar JD. Cutting edge: type I IFN reverses human Th2 commitment and stability by suppressing GATA3. Journal of Immunology 2010; 185: 813-817. DOI: 10.4049/jimmunol.1000469
82. Jordan WJ, Eskdale J, Boniotto M, Rodia M, Kellner D, Gallagher G. Modulation of the human cytokine response by interferon lambda-1 (IFN-lambda1/IL-29). Genes and Immunity 2007; 8: 13-20.
83. Kearney SJ, Delgado C, Eshleman EM, Hill KK, O'Connor BP, Lenz LL. Type I IFNs downregulate myeloid cell IFN-gamma receptor by inducing recruitment of an early growth response 3/NGFI-A binding protein 1 complex that silences ifngr1 transcription. Journal of Immunology 2013; 191: 3384-3392. DOI: 10.4049/jimmunol.1203510
84. Hillyer P, Mane VP, Schramm LM, et al. Expression profiles of human interferon-alpha and interferon-lambda subtypes are ligand- and cell-dependent. Immunology and Cell Biology 2012. DOI: 10.1038/icb.2011.109
85. Yamamoto M, Sato S, Hemmi H, et al. Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. Science 2003; 301: 640-643. DOI: 10.1126/science.1087262
86. Jiang Z, Mak TW, Sen G, Li X. Toll-like receptor 3-mediated activation of NF-kappaB and IRF3 diverges at Toll-IL-1 receptor domain-containing adapter inducing IFN-beta. Proceedings of the National Academy of Sciences of the United States of America 2004; 101: 3533-3538. DOI: 10.1073/pnas.0308496101
87. Melchjorsen J, Siren J, Julkunen I, Paludan SR, Matikainen S. Induction of cytokine expression by herpes simplex virus in human monocyte-derived macrophages and dendritic cells is dependent on virus replication and is counteracted by ICP27 targeting NF-kappaB and IRF-3. Journal of General Virology 2006; 87: 1099-1108.
88. Byrnes AA, Ma X, Cuomo P, et al. Type I interferons and IL-12: convergence and cross-regulation among mediators of cellular immunity. European Journal of Immunology 2001; 31: 2026-2034. DOI: 10.1002/1521-4141(200107)31:7<2026::AID-IMMU2026>3.0.CO;2-U
89. van Boxel-Dezaire AH, Zula JA, Xu Y, Ransohoff RM, Jacobberger JW, Stark GR. Major differences in the responses of primary human leukocyte subsets to IFN-beta. Journal of Immunology 2010; 185: 5888-5899. DOI: 10.4049/jimmunol.0902314
90. Liu BS, Janssen HL, Boonstra A. Type I and III interferons enhance IL-10R expression on human monocytes and macrophages, resulting in IL-10-mediated suppression of TLR-induced IL-12. European Journal of Immunology 2012; 42: 2431-2440. DOI: 10.1002/eji.201142360
91. Meissner N, Swain S, McInnerney K, Han S, Harmsen AG. Type-I IFN signaling suppresses an excessive IFN-gamma response and thus prevents lung damage and chronic inflammation during Pneumocystis (PC) clearance in CD4 T cell-competent mice. American Journal of Pathology 2010; 176: 2806-2818. DOI: 10.2353/ajpath.2010.091158
92. Meissner NN, Swain S, Tighe M, Harmsen A, Harmsen A. Role of type I IFNs in pulmonary complications of Pneumocystis murina infection. Journal of Immunology 2005; 174: 5462-5471.
93. Arimori Y, Nakamura R, Yamada H, et al. Type I interferon limits influenza virus-induced acute lung injury by regulation of excessive inflammation in mice. Antiviral Research 2013; 99: 230-237. DOI: 10.1016/j.antiviral.2013.05.007
94. Markowitz CE. Interferon-beta: mechanism of action and dosing issues. Neurology 2007; 68: S8-S11. DOI: 10.1212/01.wnl.0000277703.74115.d2
95. Krueger C, Hawkins K, Wong S, Enns MW, Minuk G, Rempel JD. Persistent pro-inflammatory cytokines following the initiation of pegylated IFN therapy in hepatitis C infection is associated with treatment-induced depression. Journal of Viral Hepatitis 2011; 18: e284-e291. DOI: 10.1111/j.1365-2893.2010.01408.x
96. Kumagai Y, Takeuchi O, Kato H, et al. Alveolar macrophages are the primary interferon-alpha producer in pulmonary infection with RNA viruses. Immunity 2007; 27: 240-252.
97. Verreck FA, de Boer T, Langenberg DM, van der Zanden L, Ottenhoff TH. Phenotypic and functional profiling of human proinflammatory type-1 and anti-inflammatory type-2 macrophages in response to microbial antigens and IFN-gamma- and CD40L-mediated costimulation. Journal of Leukocyte Biology 2006; 79: 285-293. DOI: 10.1189/jlb.0105015
98. Bosschaerts T, Guilliams M, Stijlemans B, et al. Tip-DC development during parasitic infection is regulated by IL-10 and requires CCL2/CCR2, IFN-gamma and MyD88 signaling. PLoS Pathogen 2010; 6: e1001045. DOI: 10.1371/journal.ppat.1001045
99. Murray PJ, Wang L, Onufryk C, Tepper RI, Young RA. T cell-derived IL-10 antagonizes macrophage function in mycobacterial infection. Journal of Immunology 1997; 158: 315-321.
100. Peppa D, Micco L, Javaid A, et al. Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection. PLoS Pathogen 2010; 6: e1001227. DOI: 10.1371/journal.ppat.1001227
101. Dunn C, Peppa D, Khanna P, et al. Temporal analysis of early immune responses in patients with acute hepatitis B virus infection. Gastroenterology 2009; 137: 1289-1300. DOI: 10.1053/j.gastro.2009.06.054
102. Ejrnaes M, Filippi CM, Martinic MM, et al. Resolution of a chronic viral infection after interleukin-10 receptor blockade. Journal of Experimental Medicine 2006; 203: 2461-2472. DOI: jem.20061462 [pii] 10.1084/jem.20061462
103. Brooks DG, Lee AM, Elsaesser H, McGavern DB, Oldstone MB. IL-10 blockade facilitates DNA vaccine-induced T cell responses and enhances clearance of persistent virus infection. Journal of Experimental Medicine 2008; 205: 533-541. DOI: jem.20071948 [pii] 10.1084/jem.20071948
104. Sun K, Torres L, Metzger DW. A detrimental effect of interleukin-10 on protective pulmonary humoral immunity during primary influenza A virus infection. Journal of Virology 2010; 84: 5007-5014. DOI: 10.1128/JVI.02408-09
105. Panuska JR, Merolla R, Rebert NA, et al. Respiratory syncytial virus induces interleukin-10 by human alveolar macrophages. Suppression of early cytokine production and implications for incomplete immunity. Journal of Clinical Investigation 1995; 96: 2445-2453.
106. Bont L, Heijnen CJ, Kavelaars A, et al. Monocyte IL-10 production during respiratory syncytial virus bronchiolitis is associated with recurrent wheezing in a one-year follow-up study. American Journal of Respiratory and Critical Care Medicine 2000; 161: 1518-1523.
107. Legg JP, Hussain IR, Warner JA, Johnston SL, Warner JO. Type 1 and type 2 cytokine imbalance in acute respiratory syncytial virus bronchiolitis. American Journal of Respiratory and Critical Care Medicine 2003; 168: 633-639.
108. Schuurhof A, Janssen R, de Groot H, et al. Local interleukin-10 production during respiratory syncytial virus bronchiolitis is associated with post-bronchiolitis wheeze. Respiratory Research 2011; 12: 121. DOI: 10.1186/1465-9921-12-121
109. Zuany-Amorim C, Haile S, Leduc D, et al. Interleukin-10 inhibits antigen-induced cellular recruitment into the airways of sensitized mice. Journal of Clinical Investigation 1995; 95: 2644-2651.
110. Borish L, Aarons A, Rumbyrt J, Cvietusa P, Negri J, Wenzel S. Interleukin-10 regulation in normal subjects and patients with asthma. Journal of Allergy and Clinical Immunology 1996; 97: 1288-1296.
111. Barnes PJ. IL-10: a key regulator of allergic disease. Clinical and Experimental Allergy 2001; 31: 667-669.
112. Justice JP, Shibata Y, Sur S, Mustafa J, Fan M, Van Scott MR. IL-10 gene knockout attenuates allergen-induced airway hyperresponsiveness in C57BL/6 mice. American Journal of Physiology. Lung Cellular and Molecular Physiology 2001; 280: L363-L368.
113. Lee CG, Homer RJ, Cohn L, et al. Transgenic overexpression of interleukin (IL)-10 in the lung causes mucus metaplasia, tissue inflammation, and airway remodeling via IL-13-dependent and -independent pathways. Journal of Biological Chemistry 2002; 277: 35466-35474.
114. Melgert BN, ten Hacken NH, Rutgers B, Timens W, Postma DS, Hylkema MN. More alternative activation of macrophages in lungs of asthmatic patients. Journal of Allergy and Clinical Immunology 2011; 127: 831-833. DOI: 10.1016/j.jaci.2010.10.045
115. Moreira AP, Cavassani KA, Hullinger R, et al. Serum amyloid P attenuates M2 macrophage activation and protects against fungal spore-induced allergic airway disease. Journal of Allergy and Clinical Immunology 2010; 126: 712-721 e717. DOI: 10.1016/j.jaci.2010.06.010
116. Ford AQ, Dasgupta P, Mikhailenko I, Smith EM, Noben-Trauth N, Keegan AD. Adoptive transfer of IL-4Ralpha+ macrophages is sufficient to enhance eosinophilic inflammation in a mouse model of allergic lung inflammation. BMC Immunology 2012; 13: 6. DOI: 10.1186/1471-2172-13-6
117. Careau E, Sirois J, Bissonnette EY. Characterization of lung hyperresponsiveness, inflammation, and alveolar macrophage mediator production in allergy resistant and susceptible rats. American Journal of Respiratory Cell and Molecular Biology 2002; 26: 579-586.
118. Robinson DS, Tsicopoulos A, Meng Q, Durham S, Kay AB, Hamid Q. Increased interleukin-10 messenger RNA expression in atopic allergy and asthma. American Journal of Respiratory Cell and Molecular Biology 1996; 14: 113-117.
119. Magnan A, van Pee D, Bongrand P, Vervloet D. Alveolar macrophage interleukin (IL)-10 and IL-12 production in atopic asthma. Allergy 1998; 53: 1092-1095.
120. Tillie-Leblond I, Pugin J, Marquette CH, et al. Balance between proinflammatory cytokines and their inhibitors in bronchial lavage from patients with status asthmaticus. American Journal of Respiratory and Critical Care Medicine 1999; 159: 487-494.
121. Colavita AM, Hastie AT, Musani AI, et al. Kinetics of IL-10 production after segmental antigen challenge of atopic asthmatic subjects. Journal of Allergy and Clinical Immunology 2000; 106: 880-886.
122. Zeibecoglou K, Ying S, Meng Q, Poulter LW, Robinson DS, Kay AB. Macrophage subpopulations and macrophage-derived cytokines in sputum of atopic and nonatopic asthmatic subjects and atopic and normal control subjects. Journal of Allergy and Clinical Immunology 2000; 106: 697-704.
123. Lim S, John M, Seybold J, et al. Increased interleukin-10 and macrophage inflammatory protein-1 alpha release from blood monocytes ex vivo during late-phase response to allergen in asthma. Allergy 2000; 55: 489-495.
124. Prasse A, Germann M, Pechkovsky DV, et al. IL-10-producing monocytes differentiate to alternatively activated macrophages and are increased in atopic patients. Journal of Allergy and Clinical Immunology 2007; 119: 464-471.
125. Bochner BS, Hudson SA, Xiao HQ, Liu MC. Release of both CCR4-active and CXCR3-active chemokines during human allergic pulmonary late-phase reactions. Journal of Allergy and Clinical Immunology 2003; 112: 930-934.
126. Liu L, Jarjour NN, Busse WW, Kelly EA. Enhanced generation of helper T type 1 and 2 chemokines in allergen-induced asthma. American Journal of Respiratory and Critical Care Medicine 2004; 169: 1118-1124.
127. Zimmermann N, King NE, Laporte J, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. Journal of Clinical Investigation 2003; 111: 1863-1874.
128. Payvandi F, Amrute S, Fitzgerald-Bocarsly P. Exogenous and endogenous IL-10 regulate IFN-alpha production by peripheral blood mononuclear cells in response to viral stimulation. Journal of Immunology 1998; 160: 5861-5868.
129. Maris CH, Chappell CP, Jacob J. Interleukin-10 plays an early role in generating virus-specific T cell anergy. BMC Immunology 2007; 8: 8.
130. Brockman MA, Kwon DS, Tighe DP, et al. IL-10 is up-regulated in multiple cell types during viremic HIV infection and reversibly inhibits virus-specific T cells. Blood 2009; 114: 346-356. DOI: 10.1182/blood-2008-12-191296
131. Wark PA, Johnston SL, Moric I, Simpson JL, Hensley MJ, Gibson PG. Neutrophil degranulation and cell lysis is associated with clinical severity in virus-induced asthma. European Respiratory Journal 2002; 19: 68-75.
132. Busse WW, Gern JE. Is interleukin-10 a "10" in virus-provoked asthma? American Journal of Respiratory and Critical Care Medicine 2005; 172: 405-406.
133. Nagarkar DR, Bowman ER, Schneider D, et al. Rhinovirus infection of allergen-sensitized and -challenged mice induces eotaxin release from functionally polarized macrophages. Journal of Immunology 2010; 185: 2525-2535. DOI: 10.4049/jimmunol.1000286
134. Gern JE, Dick EC, Lee WM, et al. Rhinovirus enters but does not replicate inside monocytes and airway macrophages. Journal of Immunology 1996; 156: 621-627.
135. Johnston SL, Papi A, Monick MM, Hunninghake GW. Rhinoviruses induce interleukin-8 mRNA and protein production in human monocytes. Journal of Infectious Diseases 1997; 175: 323-329.
136. Stockl J, Vetr H, Majdic O, Zlabinger G, Kuechler E, Knapp W. Human major group rhinoviruses downmodulate the accessory function of monocytes by inducing IL-10. Journal of Clinical Investigation 1999; 104: 957-965.
137. Parry DE, Busse WW, Sukow KA, Dick CR, Swenson C, Gern JE. Rhinovirus-induced PBMC responses and outcome of experimental infection in allergic subjects. Journal of Allergy and Clinical Immunology 2000; 105: 692-698.
138. Papadopoulos NG, Stanciu LA, Papi A, Holgate ST, Johnston SL. A defective type 1 response to rhinovirus in atopic asthma. Thorax 2002; 57: 328-332.
139. Papadopoulos NG, Stanciu LA, Papi A, Holgate ST, Johnston SL. Rhinovirus-induced alterations on peripheral blood mononuclear cell phenotype and costimulatory molecule expression in normal and atopic asthmatic subjects. Clinical and Experimental Allergy 2002; 32: 537-542.
140. Hall DJ, Bates ME, Guar L, Cronan M, Korpi N, Bertics PJ. The role of p38 MAPK in rhinovirus-induced monocyte chemoattractant protein-1 production by monocytic-lineage cells. Journal of Immunology 2005; 174: 8056-8063.
141. Laza-Stanca V, Stanciu LA, Message SD, Edwards MR, Gern JE, Johnston SL. Rhinovirus replication in human macrophages induces NF-kappaB-dependent tumor necrosis factor alpha production. Journal of Virology 2006; 80: 8248-8258.
142. Contoli M, Message SD, Laza-Stanca V, et al. Role of deficient type III interferon-lambda production in asthma exacerbations. Nature Medicine 2006; 12: 1023-1026.
143. Korpi-Steiner NL, Bates ME, Lee WM, Hall DJ, Bertics PJ. Human rhinovirus induces robust IP-10 release by monocytic cells, which is independent of viral replication but linked to type I interferon receptor ligation and STAT1 activation. Journal of Leukocyte Biology 2006; 80: 1364-1374. DOI: 10.1189/jlb.0606412
144. Khaitov MR, Laza-Stanca V, Edwards MR, et al. Respiratory virus induction of alpha-, beta- and lambda-interferons in bronchial epithelial cells and peripheral blood mononuclear cells. Allergy 2009; 64: 375-386. DOI: ALL1826 [pii] 10.1111/j.1398-9995.2008.01826.x
145. Laza-Stanca V, Message SD, Edwards MR, et al. The role of IL-15 deficiency in the pathogenesis of virus-induced asthma exacerbations. PLoS Pathogen 2011; 7: e1002114. DOI: 10.1371/journal.ppat.1002114
146. Subrata LS, Bizzintino J, Mamessier E, et al. Interactions between innate antiviral and atopic immunoinflammatory pathways precipitate and sustain asthma exacerbations in children. Journal of Immunology 2009; 183: 2793-2800. DOI: 10.4049/jimmunol.0900695
147. Wark PA, Johnston SL, Bucchieri F, et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. Journal of Experimental Medicine 2005; 201: 937-947.
148. Message SD, Laza-Stanca V, Mallia P, et al. Rhinovirus-induced lower respiratory illness is increased in asthma and related to virus load and Th1/2 cytokine and IL-10 production. Proceedings of the National Academy of Sciences of the United States of America 2008; 105: 13562-13567. DOI: 10.1073/pnas.0804181105
149. Grissell TV, Powell H, Shafren DR, et al. Interleukin-10 gene expression in acute virus-induced asthma. American Journal of Respiratory and Critical Care Medicine 2005; 172: 433-439. DOI: 200412-1621OC [pii] 10.1164/rccm.200412-1621OC
150. Wood LG, Simpson JL, Wark PA, Powell H, Gibson PG. Characterization of innate immune signalling receptors in virus-induced acute asthma. Clinical and Experimental Allergy 2011; 41: 640-648. DOI: 10.1111/j.1365-2222.2010.03669.x